Background
Substance P (SP) is one member of the tachykinin neuropeptide family that shares a carboxy-terminal sequence Phe-X-Gly-Leu-Met-NH
2 [
1], along with neurokinin A, neurokinin B and neuropeptide K, neuropeptide-γ. SP is derived from the preprotachykinin-A gene, and is synthesized in the dorsal root ganglion (DRG) neurons [
2]. SP is released through a very complex process involving some important intracellular effectors, such as extracellular calcium influx, 1,4,5-inositol trisphosphate-induced calcium release, the activation of extracellular signal-regulated kinase (ERK), cyclooxygenases (COXs) and prostaglandins, and the cyclic AMP-dependent protein kinase A (PKA) from primary afferent neurons to convey information about various noxious stimuli [
3‐
6]. Previous studies have demonstrated that SP functions as an important neurotransmitter and/or, as a primary afferent modulator in nociceptive processes, thereby potentiating excitatory input to nociceptive neurons [
7‐
10].
The biological effects of SP are mediated through binding to the specific G-protein-coupled neurokinin receptors designated neurokinin-1, -2 and -3 receptors [
11]. Once activated by SP, the neurokinin receptor induces the activation of several second messenger systems, such as phospholipase C (PLC) and adenylate cyclase, thereby increasing the consequent production of 1,4,5-inositol trisphosphate and cyclic AMP [
12]. Moreover SP has been shown to induce the activation of ERK1/2 and p38 mitogen-activated protein (MAP) kinases, nuclear factor-kappa B and protein kinase C (PKC), and thereafter to increase the production of prostaglandin E
2 and the expression of COX-2 [
13‐
15]. Interestingly, both anatomical and functional evidence have also suggested that neurokinin-1 receptors may function as auto-receptors in DRG neurons [
16,
17]. In view of the above-mentioned observations on the release and the biological effects of SP, it is considered important to clarify whether the release of SP is induced via the activation of neurokinin-1 receptor, while also elucidating what type of signaling can occur in the process of SP release via the neurokinin-1 receptor from cultured adult rat DRG neurons. Hence, the objective of the present study is designed to demonstrate whether the release of SP may be stimulated by itself through the activation of its receptors and the involvement of some important intracellular effectors (such as MAP kinase, PLC and PKC, COX and PKA) from cultured DRG neurons.
Discussion
In the present study, we demonstrated for the first time that the activation of neurokinin-1 receptor by its agonists (SP or GR73632) modulates the SP release from cultured DRG neurons through some important intracellular effectors.
During the 360 min exposure of DRG to SP (200 pg/dish), a peak response in the SP release was observed within the first 60 min, whereas a gradual decrease in the SP release level was obtained at later time points (180 and 360 min) (Fig.
1A). The release pattern of SP induced by itself may be explained by the internalization and recycling of the neurokinin-1 receptor [
24], because the immunocytochemical and Western blotting results (Figs
2A and
3) showed the existence of neurokinin-1 receptor internalization induced by SP, and it also indicated an inhibitory effect of the continuous exposure to SP on the neurokinin-1 receptor recycling. In addition, the time-dependent reduction in SP content of the DRG neurons exposed to SP provides an explanation for the existence of SP release (Fig.
2B). Our present findings are therefore in agreement with the hypothesis that SP induces its own release via its auto-receptor, the neurokinin-1 receptor [
16,
17]. Our data also indicated that SP may function as a neuromodulator in the slow release response itself from cultured DRG neurons. The precise mechanism of the association between the SP release and the neurokinin-1 receptor internalization should be revealed by further studies.
The neurokinin-1 receptor has a preferential affinity for SP [
25]. The expression of the neurokinin-1 receptor is observed mainly in the small rat DRG neurons by in situ hybridization [
26]. We have therefore focused our attention on the involvement of the neurokinin-1 receptor in the SP release from cultured DRG neurons. GR73632 (a selective agonist of the neurokinin-1 receptor) stimulated a significant increase in the release of SP via acting on the neurokinin-1 receptor. To clarify the characteristics of SP release via the neurokinin-1 receptor, we further investigated the possible involvement of several intracellular effectors, such as MAPKs, COX-2 and PLC, PKA and PKCs.
The MAPKs family contains at least three protein kinases in series: JNK, p38 MAP kinase and MEK (a kinase immediately upstream of ERK that phosphorylates the tyrosine and threonine residues on ERK1/2 required for activation). They are often involved in the intracellular transmission of extracellular signals [
27]. In our previous study, the activation of ERK1/2 was demonstrated to be involved in the SP release evoked by bradykinin [
6]. Fiebich
et al. [
13] and Yang
et al. [
28] also indicated that ERK1/2 and p38 MAP kinase can be rapidly activated by SP in a dose-dependent manner. In view of the above-mentioned observations and the results shown in Fig.
5A, p38 MAP kinase and MEK seem to play a role in increasing the release of SP. In contrast, the data shown in Fig.
5A suggest that the JNK is likely to be associated with the suppression of SP release from cultured DRG neurons, although this kinase was reported to function as an important factor involved in SP-stimulated secretion and production of inflammatory mediators in rat peritoneal mast cells [
29].
It is well known that the binding of the ligand to the neurokinin-1 receptor activates several second messenger systems, including 1,4,5-inositol trisphosphate formation via PLC activation and cyclic AMP accumulation via adenylate cyclase [
12]. The activation of cyclic AMP-dependent PKA was also reported to be involved in the SP release caused by prostaglandin E
2[
30]. However, we observed that PLC and PKA did not influence the SP release via the neurokinin-1 receptor from cultured DRG neurons.
PKC is a family of serine- and threonine-specific protein kinases, which has been suggested to function as an important intracellular signaling molecule in primary afferent nociceptors, while also being implicated in acute and chronic inflammatory as well as neuropathic pain. The activation of PKC was also reported to induce the synthesis of COX-2 and the release of prostaglandin E
2 in primary midbrain astrocytes [
31]. Previous study in our laboratory [
32] has shown that the time-dependent and transient induction of COX-2 mRNA was observed 30 min after bradykinin (a potent pro-inflammatory mediator) stimulation in cultured DRG neurons. The short-term exposure of the DRG neurons to bradykinin at 1 μM for 30 min also induced small but significant amounts of prostaglandin E
2 release depending on the activation of COX1/2. Our present findings also demonstrated a significant increase in COX-2 expression stimulated during a 60 min exposure of cultured DRG neurons to SP (Fig.
6A). Moreover, the de novo protein synthesis of COX-2 requires the activation of PKCs and MEK (Fig.
6B). In view of the above-mentioned observations and results shown in Figs
5D and
6, it is suggested that PKC isozymes including ε type play the important roles in the de novo protein synthesis of COX-2 via the neurokinin-1 receptor, and thereby increase the SP release from cultured DRG neurons.
Interestingly, our results in the present work are partially consistent with several previous observations
in vivo. For example, the activation of neurokinin-1 receptors by intrathecal injection of SP evokes thermal hyperalgesia and spinal prostaglandin E
2 release which can be reversed by spinal COX-2 inhibition and by the intrathecal delivery of the p38 MAP kinase inhibitor SB203580; spinal PKC inhibition blocks the intrathecal injection of SP-mediated thermal hyperalgesia [
34‐
37]. Moreover, the inhibition of PLC-β and PKC-ε can completely block both the neurokinin-1 receptor agonist-induced TRPV1 (transient receptor potential vanilloid subtype 1) potentiation and heat hyperalgesia [
38]. Similar to the observation reported by Zhang et al. [
38], we also observed that the activation of neurokinin-1 receptor by its agonist GR73632 to enhance the capsaicin-evoked substance P release in our latest research, which thus demonstrated that the potentiation of capsaicin-evoked substance P release by GR73632 via the activation of neurokinin-1 receptor depends on the activation of PKCs, MEK and p38 MAP kinase, PLC and COXs from cultured DRG neurons (Unpublished data). However, the detailed relationships among the activation of PLC, PKC, MAP kinases and COXs regarding the enhancement of capsaicin-evoked substance P release by GR73632 via the activation of neurokinin-1 receptor will be described in a study to be published in the not-so-distant future. Based on our findings and the above-mentioned observations reported previously, we proposed a possible molecular mechanism underlying the SP release induced by the neurokinin-1 receptor agonists (SP and GR73632) from cultured rat DRG neurons. The long-term exposure of DRG neurons to SP or GR73632 resulted in the activation of MEK, p38 MAP kinase and PKC at an early stage and thereafter induced the synthesis of COX-2, which they contribute to the SP release triggered by the neurokinin-1 receptor.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
HBT participated in the design of the study, carried out all the experiments outlined in the manuscripts, performed the data analysis and wrote the manuscript. YSL designed and performed the immunocytochemical staining, and contributed to the analysis and interpretation of the data. KA designed the immunocytochemical staining, assisted with the data analysis and interpretation. YN participated in the design of the study, assisted with the data analysis and interpretation, and wrote the manuscript. All authors have read and approved the final manuscript.